4/2
01:59 pm
anro
Alto Neuroscience (ANRO) had its price target lowered by Robert W. Baird from $41.00 to $38.00. They now have an "outperform" rating on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its price target lowered by Robert W. Baird from $41.00 to $38.00. They now have an "outperform" rating on the stock.
4/2
12:38 pm
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
4/2
10:57 am
anro
Alto Neuroscience (ANRO) had its price target lowered by JonesTrading from $49.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
Alto Neuroscience (ANRO) had its price target lowered by JonesTrading from $49.00 to $44.00. They now have a "buy" rating on the stock.
4/2
09:41 am
anro
Alto Neuroscience (ANRO) had its price target lowered by Wedbush from $22.00 to $21.00. They now have a "neutral" rating on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its price target lowered by Wedbush from $22.00 to $21.00. They now have a "neutral" rating on the stock.
4/2
08:12 am
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
4/1
04:40 pm
anro
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements [Yahoo! Finance]
Low
Report
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements [Yahoo! Finance]
4/1
04:30 pm
anro
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Medium
Report
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
3/21
01:31 am
anro
Medium
Report
3/18
09:17 am
anro
Alto Neuroscience (ANRO) had its price target raised by Robert W. Baird from $22.00 to $41.00. They now have an "outperform" rating on the stock.
Low
Report
Alto Neuroscience (ANRO) had its price target raised by Robert W. Baird from $22.00 to $41.00. They now have an "outperform" rating on the stock.
3/17
08:43 am
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
3/17
08:43 am
anro
Alto Neuroscience (ANRO) had its price target raised by Wedbush from $13.00 to $22.00. They now have a "neutral" rating on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its price target raised by Wedbush from $13.00 to $22.00. They now have a "neutral" rating on the stock.
3/16
12:08 pm
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/16
07:51 am
anro
Alto Neuroscience announces $120M private placement financing [Seeking Alpha]
Medium
Report
Alto Neuroscience announces $120M private placement financing [Seeking Alpha]
3/16
07:40 am
anro
Alto Neuroscience Announces $120 Million Private Placement Financing [Yahoo! Finance]
Low
Report
Alto Neuroscience Announces $120 Million Private Placement Financing [Yahoo! Finance]
3/16
07:03 am
anro
Alto Neuroscience Announces $120 Million Private Placement Financing
Medium
Report
Alto Neuroscience Announces $120 Million Private Placement Financing
3/16
06:23 am
anro
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
3/16
06:14 am
anro
Alto Neuroscience GAAP EPS of -$2.19 beats by $0.06 [Seeking Alpha]
Medium
Report
Alto Neuroscience GAAP EPS of -$2.19 beats by $0.06 [Seeking Alpha]
3/16
06:03 am
anro
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
Medium
Report
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
3/13
08:03 am
anro
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
Low
Report
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
2/23
08:33 am
anro
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Medium
Report
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2/17
08:02 am
anro
Alto Neuroscience (NYSE:ANRO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $28.00 price target on the stock, up previously from $27.00.
High
Report
Alto Neuroscience (NYSE:ANRO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $28.00 price target on the stock, up previously from $27.00.
2/13
08:04 am
anro
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Low
Report
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
2/3
08:54 am
anro
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment [Yahoo! Finance]
Low
Report
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment [Yahoo! Finance]
2/3
08:27 am
anro
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Low
Report
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
1/20
09:31 am
anro
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)
Medium
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)